Tirzepatide for PCOS Management

Current Evidence Status

The 2023 International Evidence-based Guideline on PCOS notes that published data examining anti-obesity agents in women with PCOS are very limited, and further research is urgently needed 2
Tirzepatide is mentioned only as a future area of interest, with the guideline stating "with the FDA approval of a new dual acting GLP1-RA along with gastric inhibitory polypeptide receptor activator (tirzepatide)...medical weight management in those with PCOS will continue to be an area of interest" 1

Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces greater reductions in blood sugar levels and body weight compared with semaglutide and dulaglutide in diabetes trials 3, 4
Given that even modest weight loss of 5% can improve metabolic and reproductive abnormalities in women with PCOS, tirzepatide's superior weight loss profile suggests potential benefit 2

Liraglutide and semaglutide demonstrate more clinical benefits for PCOS compared to shorter-acting GLP-1 RAs like exenatide 2
Semaglutide appears to be the most potent long-acting GLP-1 RA but has only been studied in one small pilot study in PCOS patients, showing benefits for anthropometric measures including visceral body fat reduction 1, 2

Physical activity, specifically resistance training, should accompany treatment to preserve lean body mass and promote weight maintenance 2, 5
Start with a lower dose (2.5mg weekly for tirzepatide based on diabetes dosing) and gradually titrate to minimize gastrointestinal side effects 5

Monitor for worsening gastrointestinal symptoms including nausea, vomiting, diarrhea, constipation, and abdominal pain 5
Evaluate for potential serious adverse events including pancreatitis, gallbladder disease, and acute kidney injury 5
Track anthropometric outcomes (weight, BMI, visceral fat), metabolic parameters (insulin resistance, glucose), and reproductive outcomes (menstrual regularity, androgen levels) 1, 2

Do not prescribe tirzepatide as first-line therapy for PCOS - current evidence does not support this, and lifestyle modification with metformin or combined oral contraceptives remain standard 2
Do not expect rapid improvements in reproductive outcomes - most studies show that 12-week protocols are insufficient to demonstrate changes in hirsutism and fertility 1, 2
Do not ignore contraindications - avoid in patients with history of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 5

More high-quality, multicenter studies of tirzepatide in PCOS are urgently needed, incorporating reproductive, metabolic, and psychological outcomes in addition to anthropometric outcomes 1, 2